{
    "nct_id": "NCT03827967",
    "official_title": "A Phase Ib Trial of Neoadjuvant PalloV-CC (Particle-delivered, Allogeneic Tumor Cell Lysate Vaccine for Colon Cancer) in Colon Cancer",
    "inclusion_criteria": "1. Stage I-IV (resectable) colon cancer patients identified prior to their definitive surgery\n2. Diagnosis definitively confirmed by endoscopic biopsy with tumor tissue slides available for analysis\n3. Asymptomatic and capable of waiting 4 weeks prior to definitive surgery\n4. ECOG 0-1 performance\n5. Not involved in other clinical trials\n6. Capable of giving informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Symptoms of obstruction or GI bleeding that necessitate more urgent surgical intervention\n2. Cancer not definitively confirmed on endoscopic biopsy (i.e., Only high-grade dysplasia or adenoma identified, even if malignancy is suspected)\n3. Known immune deficiency disease or HIV, active HBV, or active HCV\n4. Steroids or other immunosuppressants received within 6 weeks of enrollment\n5. Any colon cancer directed treatment (chemotherapy or radiation) received or planned prior to surgical resection\n6. A history of any hematologic malignancy or myeloproliferative disease within 5 years prior to enrollment\n7. Leukopenia or neutropenia within two weeks of presentation\n8. ECOG >/= 2\n9. Pregnancy (serum or urine HCG) or breast feeding\n10. Tbili >1.8, Cr >2, Hgb <10, platelet count <50,000, WBC <2,000",
    "miscellaneous_criteria": ""
}